Chr. Hansen's 2’-FL HMO receives approval for infant formula in ANZ
Food Standards Australia New Zealand (FSANZ) has approved Chr. Hansen’s 2’-FL human milk oligosaccharide (HMO) to be used in infant formulas in Australia and New Zealand. 2'-FL HMO is the most abundant and most studied human oligosaccharide in breast milk, used in infant formula around the world since 2016.
The addition of the 2’-FL HMO ingredient in infant formula is designed to produce milk closer in composition to human breast milk.
“Breastfeeding is the best way to ensure infant health and recommended by WHO. At Chr. Hansen, we further aim to support the healthy development of infants that cannot be breastfed by providing HMOs as an ingredient for infant formula,” said Dr Katja Parschat, head of Research & Development at Chr. Hansen HMO.
“The latest research shows that HMOs contribute to health benefits, such as supporting the immune system and healthy brain development. Also, HMOs are indicated to support gut maturation and resilience, as well as promotion of a balanced gut microbiome. We are happy to be able to offer our solutions to customers in Australia and New Zealand now.”
Nanoantibody technology to address aquaculture challenges
The technology is being developed as an alternative to some of the chemical methods currently...
Food and beverage businesses get ready for AI future
The challenge with implementing AI tools in food and beverage businesses is knowing where, why...
Tecpro Australia expands container cleaning solutions through Rotajet partnership
Tecpro Australia has been appointed as the Australian distributor for Rotajet's range of...
